

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Neoantigen Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
Details : Chlorotrianisene is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Neoantigen Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TACE is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TACE is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Newish Technology Beijing
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TACE is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 03, 2018
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Newish Technology Beijing
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Accuray
Deal Size : Inapplicable
Deal Type : Inapplicable
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Details : TACE is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2011
Lead Product(s) : Chlorotrianisene
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Accuray
Deal Size : Inapplicable
Deal Type : Inapplicable
